Brief: Xspray Pharma Signs License Agreement With Handa Therapeutics
12/08/2025 07:20
Aug 12 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST: XSPRAY PHARMA SIGNS LICENSE AGREEMENT WITH HANDA THERAPEUTICS – TO RECEIVE UP TO DOUBLE-DIGIT ROYALTY ON HANDA’S NET PROCEEDS LICENSE COVERS DASATINIB IN US AND ASIAN MARKETS Source text: ID:nMFN57XPyR Further company coverage: XSPRAY.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003